SciTech Development, LLC
P.O. Box 36927
Grosse Pointe Farms, MI 48236
www.SciTechDevelopment.com

Market Sector
- Specialty Pharmaceutical
- Drug Delivery

Product
- ST-001: a multi-target, nano-Fenretinide cancer therapeutic utilizing the SciTech Delivery Platform (SDP)

Stage
- Early/Mid Stage
- FDA IND granted December, 2019
- Pre-money valuation is $40M

Intellectual Property
- Worldwide license
- U.S. patent # 8709379B2
- E.U. patent # 2013016

Leadership Team
- CEO - Earle Holsapple
- CFO - Andrew Stumpf
- CSA - Ralph Parchment
- COO - Lou Scarmoutzos
- DCA - Ali Moiin

Investment
- Tiered/Seeking up to $20M
- Investment of $6M to date

Use of Proceeds
- Conduct Phase 1a/b clinical trial for ST-001
- Operating capital
- Manufacturing
- Additional R&D
- Scale management team

Law Firm
- Wilson Sonsini Goodrich & Rosati - Intellectual Property
- Immix Law Group - Corporate

Bank
- Silicon Valley Bank

Investor Relations Contact
- David R. Schaffer
  DRS@SciTechDevelopment.com
  (727)-278-8188 (US)

SCITECH DEVELOPMENT, LLC

SciTech is a clinical stage, specialty pharmaceutical company that has developed a patented, nanoparticle delivery platform, SDP, to maximize the bioavailability of water-insoluble therapeutics, while maintaining or improving safety profiles.

SciTech's lead drug candidate is ST-001, a nano-particle formulation that enables the safe, rapid, intravenous (IV) delivery of high-dose fenretinide. In thousands of patients and multiple clinical trials, fenretinide has been shown to be a safe and effective anticancer therapeutic*, with evidence of *multiple Mechanisms of Action* for greater clinical outcomes.

HIGHLIGHTS

- ST-001 solves the bioavailability problem that has plagued fenretinide since its development
- ST-001 is a significantly de-risked asset based on positive, past fenretinide activity
- IND for T-Cell Lymphomas approved by the FDA
- Orphan Drug Designation granted for several T-Cell Lymphomas
- FDA approved Phase 1a/b (equivalent to traditional Phase 1 & 2) clinical trial
- Clinical trials are confirmatory, not exploratory
- ST-001 has potential use as a companion therapeutic with other already approved drugs
- SciTech Delivery Platform (SDP) can be used to solve bioavailability problems in other drugs
- SDP has potential application for treating additional cancers, COVID-19 and other viruses
- Provides an affordable treatment cost to patients and for payors

PROBLEM: LOW DRUG BIOAVAILABILITY SEVERELY LIMITS CLINICAL USE

Many anti-cancer drug substances have low bioavailability resulting in challenges with achieving full clinical potential. Sub-therapeutic dose levels lead to insufficient delivery to the cancer cell, and unacceptable toxicity to patients. This is true of fenretinide, where low bioavailability for cancer indications has previously remained unsolved - *until now*.

SOLUTION: AN EFFECTIVE DELIVERY PLATFORM FOR ST-001 NANOFENRETINIDE

- ST-001, a nanoparticle combination of fenretinide and biocompatible phospholipids will allow for the rapid infusion of high-dose fenretinide to 1) solve bioavailability challenges, 2) avoid triglyceride toxicity, and 3) optimize therapeutic efficacy with simple infusion (IV).
- ST-001 should safely produce benefits for fenretinide bioavailability previously unattainable.
- Costs to commercialize and manufacture are believed to be reasonable.

AN EXPERIENCED MANAGEMENT TEAM

Earle Holsapple, CEO, President & Co-Founder; Director, Center for Cancer Economics, Technology Assessment, Innovation & Development (CETAID), Karmanos Cancer Institute; CEO/COO of six profitable, midsized corporations; Raised significant capital for 4 startups.

Ralph Parchment, PhD, Co-Founder and Chief Scientific Advisor; Pharmacologist; Director, Multi-Laboratory Research Program, Frederick National Laboratory for Cancer Research Discovered ST-001 while at Karmanos Cancer Institute.

Louis Scarmoutzos, PhD, Chief Operations Officer; Consultant to National Institute of Health and the National Science Foundation commercialization programs, Drug development lead; Dual proficiency in science and business.

Ali Moiin, MD, Director of Clinical Affairs; Board certified dermatologist with extensive experience in treating cutaneous T-cell lymphoma patients, Clinical Professor at Wayne State University, School of Medicine; Doctor of Medicine degree from University California, Davis.

Michael Burns, PhD, Technology Licensing Officer; Former President and COO of Ferndale Pharma Group; Extensive pharmaceutical industry experience including product development, R&D, sales and marketing, licensing and M&A.

Andrew Stumpf, CPA, MBA, Chief Financial Officer; Financial, accounting, and valuation advisory services to Fortune 500 and mid-market companies; Partner with Storm Lake Capital, VP for Stout Risius Ross Advisors, and auditor with Ernst & Young.

David R. Schaffer, Director of Business Development and Investor Relations; Experience in global equity markets, investment banking, investor relations and strategic advisory to public/private funds; Most notably as Managing Director with Raymond James, and previously with Advest.

Lori Kavle, Director of Strategic and Corporate Partnering; International experience in pharma and biohealth including strategic advisory, partnering, business development and marketing; Executive positions at Bristol Myers Squibb, Novartis, Sanofi, PluroGen, and Dendrite Intl., (IQVIA).

Milestones and Achievements

- ST-001 Patent granted in 2013
- Patent extension to 2030
- Orphan Drug Designation granted 2018 for Cutaneous T-Cell Lymphomas (CTCL) and Peripheral T-Cell Lymphomas (PTCL)
- IND received from the FDA in December, 2019 for T-Cell Lymphomas

- ST-001 for COVID-19:
  - IND application filed with the FDA in June, 2021
  - Applied for a provisional patent related to COVID-19 in 2020

Partners and Collaborators

- National Cancer Institute
- National Institutes of Health
- Karmanos Cancer Institute
  Detroit, MI
- Wayne State University
  Detroit, MI
- Campbell University PERC
  Buies Creek, NC
- Rush University Medical Center
  Chicago, IL
- Spectrum Health Systems,
  Grand Rapids, MI
- Ferndale Pharma Group,
  Ferndale, MI
- Plough Manufacturing,
  Memphis, TN
- BD/M Collective,
  Henderson, NV
- biomedwoRx:
  Life Sciences Consulting
  San Diego, CA

SCITECH DEVELOPMENT
Advancing Cancer Treatment *Through Safer Drug Delivery*

ST-001 AND FENRETINIDE AS A THERAPEUTIC AGENT

The National Cancer Institute saw the vast potential of fenretinide, and subsequently funded its development. Dr. Ralph Parchment and Earle Holsapple founded SciTech, and led the effort to find the solution to enhance fenretinide's bioavailability, thus developing SciTech's Delivery Platform and Lead Drug Candidate, ST-001.



Fenretinide (API)

Fenretinide was first developed by Johnson & Johnson and has been clinically tested as a breast cancer prevention drug in more than 3,000 women where it was demonstrated to be safe after long periods of use. Fenretinide evolved into a cancer therapeutic because it had been shown to also be partially effective in the prevention study and within numerous subsequent preclinical and clinical studies.

In addition, the recent discovery of fenretinide's immunotherapeutic effect, in which a reactivated natural immune response compliments the previously understood safe, direct, chemotherapeutic effect, results in a unique, genetically directed process of cancer cell destruction which will further enhance ST-001's value.

UNIQUE QUALITIES OF ST-001

The unique qualities of ST-001 nanoFenretinide are defined by the nature and proportions of all the ingredients that are assembled and manufactured in a very specific manner.

ST-001 IS EXPECTED TO:

- Overcome the current drug delivery and bioavailability challenges seen with fenretinide
- Safely achieve therapeutically effective doses
- Avoid toxic side effects observed with other delivery systems and formulations
- Deliver a 6-fold higher formulation strength than conventional IV formulations
- Safely deliver to target cancer cells at least a 15-fold higher concentration of fenretinide than reference formulations**
- Enable potential use in numerous other cancers

A LARGE TARGET MARKET

The US market opportunity for T-cell lymphoma (T-cell), Small Cell Lung Cancer (SCLC) and Metastatic Breast Cancer is over $2B. ST-001 will address a broader cancer market of $5B to $25B+ where research has demonstrated patients are likely to respond to fenretinide alone or in synergistic combination with other anticancer agents. The initial indications were chosen, not because of market size, but because of prior directional clinical efficacy, and where data suggest these indications have the highest probability of responding to ST-001 as a mono-therapy. This should result in quicker FDA approval and commercial launch. Based on clinical data, ST-001 is anticipated to be efficacious in other lymphomas, leukemia and additional cancer types such as small cell lung cancer, colo-rectal, head & neck, ovarian, cervical and pancreatic. These cancers and are expected to be targeted in the near future.

COMMERCIALIZATION STRATEGY

- The immediate goal is to commercialize ST-001 in T-Cell Lymphomas and Small Cell Lung Cancer, as evidenced by the FDA guidance on the rapid phase 1a/1b clinical trial strategy.
- SciTech's focus is to develop strategic partnerships with companies in the pharmaceutical and biotech sector that want to expand their current sales and product pipelines or gain a foothold in these oncology domains.

CONCLUSION

Based on the body of evidence compiled from numerous studies and published literature, SciTech has concluded that no other current fenretinide-based drug product is capable of delivering the established therapeutic efficacy of fenretinide in cancer patients like ST-001.

ST-001 will become a first-line, highly effective, widely-used, and affordable anti-cancer therapeutic agent

**Source: NIH*
*** Data is based on current fenretinide formulations*